Details of the Drug Combination

General Information of Drug Combination (ID: DCRIHT1)

Drug Combination Name
Olaparib Paclitaxel
Indication
Disease Entry Status REF
Gastric Cancer Phase 1 [1]
Component Drugs Olaparib   DM8QB1D Paclitaxel   DMLB81S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Olaparib
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Approved [2]
Pancreatic cancer 2C10 Phase 3 [3]
Prostate cancer 2C82.0 Phase 3 [3]
Olaparib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Olaparib Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Olaparib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Olaparib Interacts with 20 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Increases Phosphorylation [8]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [8]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [8]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Phosphorylation [8]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Decreases Activity [9]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [8]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [10]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [10]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [8]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [10]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [10]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [10]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Expression [11]
Bromodomain-containing protein 4 (BRD4) OT2Y2TCW BRD4_HUMAN Affects Response To Substance [10]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Affects Response To Substance [12]
DNA mismatch repair protein Msh3 (MSH3) OTD3YPVL MSH3_HUMAN Decreases Response To Substance [13]
Fumarate hydratase, mitochondrial (FH) OTEQWU6Q FUMH_HUMAN Increases Response To Substance [14]
Breast cancer type 2 susceptibility protein (BRCA2) OTF1XSV1 BRCA2_HUMAN Affects Response To Substance [12]
Succinate dehydrogenase iron-sulfur subunit, mitochondrial (SDHB) OTRE1M1T SDHB_HUMAN Increases Response To Substance [14]
Ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1) OTS8G0EN BAP1_HUMAN Increases Response To Substance [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 DOT(s)
Indication(s) of Paclitaxel
Disease Entry ICD 11 Status REF
Breast carcinoma N.A. Approved [4]
Cutaneous melanoma 2C30 Approved [4]
Cutaneous squamous cell carcinoma 2C30 Approved [4]
Epithelial ovarian cancer 2B5D Approved [4]
Extragonadal germ cell tumor N.A. Approved [4]
Fallopian tube neoplasm N.A. Approved [4]
Gastroesophageal junction adenocarcinoma 2B71 Approved [4]
Inflammatory breast cancer 2C62 Approved [4]
Kaposi sarcoma 2B57 Approved [4]
Lung adenocarcinoma N.A. Approved [4]
Lung cancer 2C25.0 Approved [4]
Non-small-cell lung cancer 2C25.Y Approved [4]
Ocular hypertension 9C61.01 Approved [4]
Ovarian neoplasm N.A. Approved [4]
Ovarian serous cystadenocarcinoma N.A. Approved [4]
Pain MG30-MG3Z Approved [4]
Pancreatic ductal carcinoma 2C10.0 Approved [4]
Primary peritoneal carcinoma N.A. Approved [4]
Testicular germ cell tumor N.A. Approved [4]
Urethral cancer 2C93 Approved [4]
Lung large cell carcinoma N.A. Investigative [4]
Paclitaxel Interacts with 11 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [29]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [30]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [31]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [32]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [33]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [34]
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [35]
Multidrug resistance protein 3 (ABCB4) DTZRMK5 MDR3_HUMAN Substrate [36]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [37]
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [38]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [39]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DTP(s)
Paclitaxel Interacts with 478 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Expression [40]
ATP-binding cassette sub-family C member 10 (ABCC10) OT2JRWWJ MRP7_HUMAN Increases Expression [41]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [41]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Response To Substance [42]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [43]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [44]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Response To Substance [45]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Increases Transport [33]
Cyclin-dependent kinase 20 (CDK20) OTOLNN68 CDK20_HUMAN Decreases Expression [46]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) OTG7J4BP PPBT_HUMAN Increases ADR [16]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Increases ADR [16]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [47]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [48]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Decreases Expression [46]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [49]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [49]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [21]
Poly polymerase 1 (PARP1) OTIESHK4 PARP1_ARATH Increases ADR [16]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [50]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Increases Activity [51]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [52]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Expression [17]
Arylamine N-acetyltransferase 1 (NAT1) OTCCNQ3H ARY1_HUMAN Decreases Activity [53]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Decreases Expression [54]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Decreases Expression [47]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [47]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Activity [55]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Decreases Activity [55]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Activity [55]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [56]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) OTBPCU2O TR10A_HUMAN Increases Expression [57]
DNA fragmentation factor subunit alpha (DFFA) OTFPFMT8 DFFA_HUMAN Decreases Expression [19]
Sulfhydryl oxidase 1 (QSOX1) OT4ZPK4P QSOX1_HUMAN Decreases Expression [18]
Serine/threonine-protein kinase PLK4 (PLK4) OTV8KZDZ PLK4_HUMAN Decreases Expression [18]
TNF receptor-associated factor 5 (TRAF5) OTSBTLO0 TRAF5_HUMAN Decreases Expression [18]
Myc box-dependent-interacting protein 1 (BIN1) OTK8O0X8 BIN1_HUMAN Increases Expression [58]
Nucleoside diphosphate kinase, mitochondrial (NME4) OT2JTT42 NDKM_HUMAN Decreases Expression [19]
Potassium channel subfamily K member 3 (KCNK3) OTWMAV6G KCNK3_HUMAN Increases Expression [19]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Increases Expression [49]
Acyl-coenzyme A thioesterase 8 (ACOT8) OTHY684G ACOT8_HUMAN Decreases Expression [59]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [60]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [57]
Neuropilin-1 (NRP1) OTCGULYV NRP1_HUMAN Increases Expression [58]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Increases Expression [61]
Mitogen-activated protein kinase 13 (MAPK13) OT0W9GE7 MK13_HUMAN Increases Expression [19]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [62]
High affinity copper uptake protein 1 (SLC31A1) OTXLRTUB COPT1_HUMAN Increases Expression [41]
ATP-binding cassette sub-family C member 5 (ABCC5) OT34G4US MRP5_HUMAN Increases Expression [41]
N-glycosylase/DNA lyase (OGG1) OTJ97TF3 OGG1_HUMAN Increases Expression [19]
Retinoschisin (RS1) OTEW1ZM5 XLRS1_HUMAN Decreases Secretion [63]
Kunitz-type protease inhibitor 2 (SPINT2) OTQV7BKQ SPIT2_HUMAN Decreases Expression [58]
Adenylate cyclase type 6 (ADCY6) OTFOY4WW ADCY6_HUMAN Decreases Expression [18]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Increases Expression [61]
Mitotic checkpoint protein BUB3 (BUB3) OTU91HAU BUB3_HUMAN Increases Expression [19]
Phospholipid phosphatase 2 (PLPP2) OT0BQAXX PLPP2_HUMAN Decreases Expression [58]
Myelin protein zero-like protein 2 (MPZL2) OTKFNDUI MPZL2_HUMAN Decreases Expression [58]
Dual specificity protein phosphatase CDC14B (CDC14B) OTAESVOZ CC14B_HUMAN Decreases Expression [46]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [19]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [64]
Death effector domain-containing protein (DEDD) OTIL349E DEDD_HUMAN Decreases Expression [18]
Serine hydrolase RBBP9 (RBBP9) OT0Z04L6 RBBP9_HUMAN Decreases Expression [18]
Tumor necrosis factor ligand superfamily member 13 (TNFSF13) OT90OWIO TNF13_HUMAN Increases Expression [46]
ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial (CLPX) OTIT4JL0 CLPX_HUMAN Increases Expression [19]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Increases Expression [46]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Affects Expression [65]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Decreases Expression [18]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Decreases Expression [66]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [46]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [19]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Expression [46]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [67]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [58]
Collagen alpha-1(IV) chain (COL4A1) OTL6D1YE CO4A1_HUMAN Increases Expression [58]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [68]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Increases Phosphorylation [69]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [70]
Thy-1 membrane glycoprotein (THY1) OTVONVTB THY1_HUMAN Increases Expression [58]
Apolipoprotein D (APOD) OTT77XW8 APOD_HUMAN Increases Expression [58]
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA) OTWJTCRK PCCA_HUMAN Decreases Expression [19]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [64]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [71]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [72]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [73]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Increases Expression [74]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [75]
Gelsolin (GSN) OT4KS2UU GELS_HUMAN Decreases Expression [18]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Increases Phosphorylation [76]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [46]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Decreases Expression [59]
Prosaposin (PSAP) OTUOEKY7 SAP_HUMAN Decreases Expression [18]
Collagen alpha-2(IV) chain (COL4A2) OTJK1LKN CO4A2_HUMAN Increases Expression [58]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [58]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [77]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [71]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Localization [78]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [79]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [80]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [80]
Collagen alpha-1(VI) chain (COL6A1) OTYKSCOB CO6A1_HUMAN Increases Expression [58]
Collagen alpha-2(VI) chain (COL6A2) OTQC6PPO CO6A2_HUMAN Increases Expression [58]
ADP/ATP translocase 1 (SLC25A4) OTKYLK2J ADT1_HUMAN Decreases Expression [18]
Bone morphogenetic protein 4 (BMP4) OTPZMDFH BMP4_HUMAN Decreases Expression [22]
Elongation factor 2 (EEF2) OTZ7SZ39 EF2_HUMAN Decreases Expression [18]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Increases Expression [81]
Interleukin-1 receptor type 1 (IL1R1) OTTU8959 IL1R1_HUMAN Decreases Expression [19]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Increases Expression [82]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [83]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Decreases Expression [58]
Integrin beta-6 (ITGB6) OTI3DJ7U ITB6_HUMAN Decreases Expression [58]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [64]
DNA ligase 1 (LIG1) OTEEQS43 DNLI1_HUMAN Decreases Expression [18]
Sodium/hydrogen exchanger 1 (SLC9A1) OT6HNHFV SL9A1_HUMAN Decreases Activity [84]
Integrin alpha-L (ITGAL) OTCUQAIS ITAL_HUMAN Decreases Expression [72]
Ephrin-A1 (EFNA1) OTU2NUA2 EFNA1_HUMAN Decreases Expression [58]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [46]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Increases Expression [71]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) OTBZKX4P ROA2_HUMAN Decreases Expression [18]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [58]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [59]
Follicle-stimulating hormone receptor (FSHR) OT9MVMLI FSHR_HUMAN Decreases Expression [22]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [80]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Increases Activity [85]
Signal transducer CD24 (CD24) OT7CODJ4 CD24_HUMAN Decreases Expression [58]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [86]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Decreases Expression [58]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Increases Expression [58]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [22]
Long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADL) OTP7Y0UF ACADL_HUMAN Decreases Expression [19]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Expression [67]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Decreases Expression [46]
Adenylosuccinate synthetase isozyme 2 (ADSS2) OTW26XXB PURA2_HUMAN Decreases Expression [19]
RAC-beta serine/threonine-protein kinase (AKT2) OTBB632K AKT2_HUMAN Increases Phosphorylation [87]
Heterogeneous nuclear ribonucleoprotein H (HNRNPH1) OTFRWOLM HNRH1_HUMAN Decreases Expression [18]
Stress-induced-phosphoprotein 1 (STIP1) OT7TXLOX STIP1_HUMAN Increases Expression [19]
Syndecan-2 (SDC2) OTEEHY1D SDC2_HUMAN Increases Expression [58]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Phosphorylation [22]
Tyrosine-protein phosphatase non-receptor type 7 (PTPN7) OTXYSIIV PTN7_HUMAN Increases Expression [19]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [19]
Fibrillin-1 (FBN1) OTYCJT63 FBN1_HUMAN Increases Expression [58]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [64]
Pigment epithelium-derived factor (SERPINF1) OTWZH98J PEDF_HUMAN Increases Expression [58]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [88]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [89]
Collagen alpha-1(XVIII) chain (COL18A1) OTJFUH6O COIA1_HUMAN Increases Expression [58]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Activity [90]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Decreases Expression [19]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [80]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [91]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Activity [92]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Expression [93]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [94]
Isocitrate dehydrogenase , mitochondrial (IDH2) OTTQA4PB IDHP_HUMAN Decreases Expression [18]
4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1) OTNWHUJ1 AL9A1_HUMAN Increases Expression [19]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Decreases Expression [59]
Centromere protein F (CENPF) OT7AG0SW CENPF_HUMAN Increases Expression [95]
Caspase-4 (CASP4) OTVQTV1L CASP4_HUMAN Increases Expression [46]
NADH dehydrogenase flavoprotein 1, mitochondrial (NDUFV1) OTEVK4WW NDUV1_HUMAN Decreases Expression [18]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [96]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Decreases Expression [59]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Expression [19]
Cyclin-dependent kinase 7 (CDK7) OTAO19PQ CDK7_HUMAN Increases Activity [97]
Palmitoyl-protein thioesterase 1 (PPT1) OTM3S4DE PPT1_HUMAN Decreases Expression [59]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Decreases Expression [18]
Matrix metalloproteinase-16 (MMP16) OTSFQ2BJ MMP16_HUMAN Decreases Expression [46]
Caspase-5 (CASP5) OT0F2THD CASP5_HUMAN Increases Expression [46]
Cyclin-H (CCNH) OTKDU3SR CCNH_HUMAN Increases Expression [19]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1) OTK71JYU TCP4_HUMAN Decreases Expression [19]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [58]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Expression [46]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Expression [46]
Cadherin-11 (CDH11) OTIZKPTF CAD11_HUMAN Increases Expression [58]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Decreases Expression [58]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [81]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Increases Activity [98]
Eukaryotic initiation factor 4A-I (EIF4A1) OTMTBX6N IF4A1_HUMAN Decreases Expression [19]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Increases Expression [99]
Ras-related C3 botulinum toxin substrate 1 (RAC1) OTKRO61U RAC1_HUMAN Decreases Expression [18]
SH3 domain-binding protein 2 (SH3BP2) OT90JNBS 3BP2_HUMAN Decreases Expression [19]
General transcription factor II-I (GTF2I) OTUYL1TQ GTF2I_HUMAN Decreases Expression [18]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Increases Expression [19]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [80]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [41]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [60]
Copper-transporting ATPase 1 (ATP7A) OTMR3GXP ATP7A_HUMAN Increases Expression [41]
Protein kinase C delta type (PRKCD) OTSEH90E KPCD_HUMAN Affects Localization [70]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [21]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [46]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [49]
Heat shock protein beta-3 (HSPB3) OTE67YM5 HSPB3_HUMAN Increases Expression [19]
Lymphocyte cytosolic protein 2 (LCP2) OT57KE22 LCP2_HUMAN Increases Expression [19]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Increases Expression [46]
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) OTS3FVTY M3K1_HUMAN Increases Cleavage [92]
MAGUK p55 subfamily member 3 (MPP3) OTNOL0HA MPP3_HUMAN Increases Expression [19]
Rho-associated protein kinase 1 (ROCK1) OTSXYVW1 ROCK1_HUMAN Increases Expression [18]
Short transient receptor potential channel 3 (TRPC3) OTNR61OD TRPC3_HUMAN Increases Expression [19]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) OTTUU92F ENPP2_HUMAN Increases Expression [58]
Protein-tyrosine kinase 6 (PTK6) OT7NWIQ0 PTK6_HUMAN Increases Expression [18]
Interleukin-18 (IL18) OTBB2A8O IL18_HUMAN Increases Expression [67]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Increases Expression [19]
Src substrate cortactin (CTTN) OTJRG4ES SRC8_HUMAN Decreases Expression [19]
Caprin-1 (CAPRIN1) OTEJAMS3 CAPR1_HUMAN Decreases Expression [46]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Expression [46]
Periostin (POSTN) OTWP62UA POSTN_HUMAN Increases Expression [58]
Procollagen C-endopeptidase enhancer 1 (PCOLCE) OTJXOAN4 PCOC1_HUMAN Increases Expression [58]
Transcription factor E2F5 (E2F5) OT1XWING E2F5_HUMAN Increases Expression [18]
Microtubule-associated protein RP/EB family member 1 (MAPRE1) OTCVQD60 MARE1_HUMAN Decreases Localization [100]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [21]
Transcriptional regulator QRICH1 (QRICH1) OTPVAX04 QRIC1_HUMAN Increases Phosphorylation [101]
Parafibromin (CDC73) OT6JASZ1 CDC73_HUMAN Decreases Expression [46]
Inactive caspase-12 (CASP12) OTY2W6FG CASPC_HUMAN Decreases Expression [60]
Heme A synthase COX15 (COX15) OTUIYHIW COX15_HUMAN Decreases Expression [18]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [102]
Cell division cycle and apoptosis regulator protein 1 (CCAR1) OTUXLQZZ CCAR1_HUMAN Increases Expression [46]
NAD-dependent protein deacetylase sirtuin-2 (SIRT2) OT5Q6SVK SIR2_HUMAN Decreases Expression [64]
Abnormal spindle-like microcephaly-associated protein (ASPM) OTKXQMNA ASPM_HUMAN Increases Expression [61]
Phospholipid-transporting ATPase ABCA7 (ABCA7) OT51S50X ABCA7_HUMAN Increases Expression [41]
Centromere protein S (CENPS) OTZ4J391 CENPS_HUMAN Increases Expression [46]
NAD-dependent protein deacylase sirtuin-6 (SIRT6) OTF755ZO SIR6_HUMAN Decreases Expression [64]
Cholesterol transporter ABCA5 (ABCA5) OT4B9D92 ABCA5_HUMAN Increases Expression [41]
MAP kinase-activating death domain protein (MADD) OTUFYVGG MADD_HUMAN Decreases Expression [18]
Mucin-16 (MUC16) OTHPPE67 MUC16_HUMAN Decreases Expression [103]
Rap guanine nucleotide exchange factor 5 (RAPGEF5) OT53VS75 RPGF5_HUMAN Increases Expression [19]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Decreases Expression [22]
Transcription factor AP-2 gamma (TFAP2C) OTUDIW05 AP2C_HUMAN Decreases Expression [58]
Caspase-10 (CASP10) OTE6J88E CASPA_HUMAN Increases Expression [46]
Engulfment and cell motility protein 3 (ELMO3) OTQHO9VM ELMO3_HUMAN Increases Expression [19]
p53 apoptosis effector related to PMP-22 (PERP) OTP0YL53 PERP_HUMAN Increases Expression [46]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [104]
Cell division cycle 5-like protein (CDC5L) OTTPFUU5 CDC5L_HUMAN Decreases Expression [46]
M-phase phosphoprotein 6 (MPHOSPH6) OT6E2S48 MPH6_HUMAN Decreases Expression [19]
Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB) OTUKPFOK ROAA_HUMAN Decreases Expression [18]
Transmembrane protein 243 (TMEM243) OT8NQ79G TM243_HUMAN Increases Expression [105]
Cell division cycle-associated protein 7 (CDCA7) OT12HDZY CDCA7_HUMAN Decreases Expression [46]
Transmembrane gamma-carboxyglutamic acid protein 4 (PRRG4) OT2SZQI7 TMG4_HUMAN Decreases Expression [58]
TRIO and F-actin-binding protein (TRIOBP) OTGB5WHC TARA_HUMAN Increases Expression [19]
ATP-binding cassette sub-family B member 6 (ABCB6) OTPGZFES ABCB6_HUMAN Decreases Expression [41]
Bridging integrator 3 (BIN3) OTMIWWDW BIN3_HUMAN Decreases Expression [19]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Expression [60]
NAD-dependent protein deacetylase sirtuin-7 (SIRT7) OT5M4OT4 SIR7_HUMAN Decreases Expression [64]
Olfactomedin-like protein 3 (OLFML3) OTDN45FN OLFL3_HUMAN Increases Expression [58]
G2 and S phase-expressed protein 1 (GTSE1) OTPP742Z GTSE1_HUMAN Increases Expression [19]
ETS homologous factor (EHF) OTY6TPWD EHF_HUMAN Decreases Expression [58]
Programmed cell death 1 ligand 1 (CD274) OTJ0VFDL PD1L1_HUMAN Increases Expression [106]
DNA polymerase kappa (POLK) OTKZ38JH POLK_HUMAN Decreases Expression [18]
Protein Hook homolog 1 (HOOK1) OTTTKV7V HOOK1_HUMAN Decreases Expression [58]
PR domain zinc finger protein 4 (PRDM4) OTD9PAZJ PRDM4_HUMAN Decreases Expression [19]
F-box only protein 5 (FBXO5) OTTR957W FBX5_HUMAN Affects Expression [65]
Neurabin-1 (PPP1R9A) OTJL2TOC NEB1_HUMAN Decreases Expression [18]
Matrix metalloproteinase-17 (MMP17) OT5TMIQ6 MMP17_HUMAN Decreases Expression [46]
Microtubule-associated protein RP/EB family member 3 (MAPRE3) OTSCLETV MARE3_HUMAN Affects Localization [100]
Cyclin-D-binding Myb-like transcription factor 1 (DMTF1) OTDKO9OO DMTF1_HUMAN Decreases Expression [18]
RuvB-like 2 (RUVBL2) OTGWJ4T4 RUVB2_HUMAN Decreases Expression [19]
C-type lectin domain family 11 member A (CLEC11A) OT9KBH7C CLC11_HUMAN Increases Expression [58]
Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) OTND26XR TN13B_HUMAN Increases Expression [46]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5) OT03QCLM ATF5_HUMAN Decreases Expression [18]
Protein-arginine deiminase type-2 (PADI2) OTT40K94 PADI2_HUMAN Decreases Expression [19]
Mitochondrial import inner membrane translocase subunit Tim22 (TIMM22) OTJMHX1V TIM22_HUMAN Increases Expression [19]
Small ribosomal subunit protein mS40 (MRPS18B) OT1K9PFX RT18B_HUMAN Decreases Expression [19]
Transforming acidic coiled-coil-containing protein 3 (TACC3) OTRNEZTA TACC3_HUMAN Decreases Expression [19]
Sorting nexin-10 (SNX10) OT05B7BT SNX10_HUMAN Affects Response To Substance [24]
Superoxide dismutase (SOD2) OT08HOR5 Q4ZJI1_HUMAN Increases ADR [16]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Affects Response To Substance [24]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Response To Substance [107]
Phospholipid phosphatase 1 (PLPP1) OT0IIMI5 PLPP1_HUMAN Decreases Response To Substance [108]
Interleukin-17 receptor B (IL17RB) OT0KDNSF I17RB_HUMAN Decreases Response To Substance [108]
Oxysterol-binding protein-related protein 10 (OSBPL10) OT0TFMBE OSB10_HUMAN Affects Response To Substance [24]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13) OT0UOKIT NDUAD_HUMAN Affects Response To Substance [24]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [24]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Response To Substance [109]
Condensin complex subunit 3 (NCAPG) OT1AI9EO CND3_HUMAN Affects Response To Substance [24]
Integrin beta-5 (ITGB5) OT21MF51 ITB5_HUMAN Decreases Response To Substance [44]
NADH dehydrogenase 1 beta subcomplex subunit 7 (NDUFB7) OT2CHQQ1 NDUB7_HUMAN Affects Response To Substance [24]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Affects Response To Substance [24]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25) OT2MR6O2 SNR25_HUMAN Affects Response To Substance [24]
Epidermal growth factor-like protein 6 (EGFL6) OT331X59 EGFL6_HUMAN Decreases Response To Substance [27]
Biglycan (BGN) OT3AV6IF PGS1_HUMAN Affects Response To Substance [24]
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Affects Response To Substance [110]
Collagen alpha-1(VII) chain (COL7A1) OT3MIRZJ CO7A1_HUMAN Increases Response To Substance [108]
Solute carrier family 12 member 2 (SLC12A2) OT3ZJ3LH S12A2_HUMAN Decreases Response To Substance [108]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2) OT4717TF NDUB2_HUMAN Affects Response To Substance [24]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Affects Response To Substance [24]
Deoxycytidylate deaminase (DCTD) OT4FLFT4 DCTD_HUMAN Affects Response To Substance [24]
Sorcin (SRI) OT4R3EAC SORCN_HUMAN Decreases Response To Substance [111]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Affects Response To Substance [67]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Affects Response To Substance [24]
MARVEL domain-containing protein 1 (MARVELD1) OT5CPOJE MALD1_HUMAN Increases Response To Substance [112]
Small ribosomal subunit protein uS15m (MRPS15) OT5HRAPP RT15_HUMAN Affects Response To Substance [24]
RAC-gamma serine/threonine-protein kinase (AKT3) OT5M2LFI AKT3_HUMAN Affects Response To Substance [87]
Signal recognition particle receptor subunit alpha (SRPRA) OT5NMYTY SRPRA_HUMAN Affects Response To Substance [24]
Annexin A1 (ANXA1) OT5OFDJC ANXA1_HUMAN Increases Response To Substance [108]
Beta-sarcoglycan (SGCB) OT5R5LAT SGCB_HUMAN Affects Response To Substance [24]
Collagen alpha-2(V) chain (COL5A2) OT5VOSQE CO5A2_HUMAN Decreases Response To Substance [27]
Transmembrane protein 135 (TMEM135) OT63ZT3X TM135_HUMAN Affects Response To Substance [24]
Farnesyl pyrophosphate synthase (FDPS) OT6CKWV5 FPPS_HUMAN Increases Response To Substance [44]
Ferritin heavy chain (FTH1) OT6IFS0O FRIH_HUMAN Decreases Response To Substance [44]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Increases Response To Substance [44]
Claudin-3 (CLDN3) OT71MN9S CLD3_HUMAN Decreases Response To Substance [108]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [24]
DNA-binding protein RFX5 (RFX5) OT73KJ5P RFX5_HUMAN Decreases Response To Substance [44]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Response To Substance [113]
Large ribosomal subunit protein P1 (RPLP1) OT7B0SIB RLA1_HUMAN Decreases Response To Substance [44]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Decreases Response To Substance [114]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Affects Response To Substance [24]
Peroxisomal multifunctional enzyme type 2 (HSD17B4) OT8733D7 DHB4_HUMAN Affects Response To Substance [24]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Response To Substance [115]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Affects Response To Substance [116]
Thrombomodulin (THBD) OT8VHLKY TRBM_HUMAN Decreases Response To Substance [117]
Transcriptional repressor CTCF (CTCF) OT8ZB70U CTCF_HUMAN Decreases Response To Substance [44]
Neuron navigator 3 (NAV3) OT97M1TR NAV3_HUMAN Affects Response To Substance [24]
Solute carrier family 22 member 18 (SLC22A18) OT9C3KR4 S22AI_HUMAN Decreases Response To Substance [108]
Gamma-interferon-inducible lysosomal thiol reductase (IFI30) OT9DERT1 GILT_HUMAN Decreases Response To Substance [44]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Response To Substance [44]
Beta-glucuronidase (GUSB) OT9N1DK3 BGLR_HUMAN Affects Response To Substance [24]
FXYD domain-containing ion transport regulator 3 (FXYD3) OT9PPRHE FXYD3_HUMAN Increases Response To Substance [44]
Proteasome subunit beta type-6 (PSMB6) OT9VXPNW PSB6_HUMAN Affects Response To Substance [24]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3) OTA2TBWS HMGN3_HUMAN Affects Response To Substance [24]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Response To Substance [44]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4) OTA6ICI2 NUD4B_HUMAN Affects Response To Substance [24]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Response To Substance [118]
Proteasome subunit alpha type-4 (PSMA4) OTAD2XXI PSA4_HUMAN Affects Response To Substance [24]
POM121 and ZP3 fusion protein (POMZP3) OTAH2JOK POZP3_HUMAN Affects Response To Substance [24]
Mediator of RNA polymerase II transcription subunit 4 (MED4) OTALFN4S MED4_HUMAN Affects Response To Substance [24]
snRNA-activating protein complex subunit 1 (SNAPC1) OTAPN1NI SNPC1_HUMAN Increases Response To Substance [108]
Collagen alpha-3(VI) chain (COL6A3) OTAS6R6I CO6A3_HUMAN Affects Response To Substance [24]
MAP kinase-activated protein kinase 5 (MAPKAPK5) OTAZHPVK MAPK5_HUMAN Affects Response To Substance [24]
Desmoplakin (DSP) OTB2MOP8 DESP_HUMAN Affects Response To Substance [24]
Large ribosomal subunit protein mL40 (MRPL40) OTB2QZDY RM40_HUMAN Affects Response To Substance [24]
Large ribosomal subunit protein uL16 (RPL10) OTBHOZGC RL10_HUMAN Affects Response To Substance [24]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Response To Substance [119]
Probable ATP-dependent RNA helicase DDX23 (DDX23) OTBJHS8C DDX23_HUMAN Affects Response To Substance [24]
Coatomer subunit epsilon (COPE) OTBKHBT7 COPE_HUMAN Affects Response To Substance [24]
Protein FAM3C (FAM3C) OTBR6U9G FAM3C_HUMAN Affects Response To Substance [24]
Transmembrane protein 134 (TMEM134) OTBX9H9D TM134_HUMAN Affects Response To Substance [24]
Tight junction protein ZO-3 (TJP3) OTC1K8HC ZO3_HUMAN Decreases Response To Substance [108]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Affects Response To Substance [120]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C) OTCLOV90 CDN2C_HUMAN Affects Response To Substance [24]
Cytochrome c oxidase copper chaperone (COX17) OTCP4LH2 COX17_HUMAN Affects Response To Substance [24]
Trefoil factor 1 (TFF1) OTCYQH4F TFF1_HUMAN Increases Response To Substance [44]
S-phase kinase-associated protein 2 (SKP2) OTD5B41X SKP2_HUMAN Affects Response To Substance [24]
Integrin alpha-1 (ITGA1) OTDITIST ITA1_HUMAN Increases Response To Substance [27]
Stathmin (STMN1) OTDJ4RV0 STMN1_HUMAN Affects Response To Substance [121]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Affects Response To Substance [24]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Decreases Response To Substance [44]
Superkiller complex protein 8 (SKIC8) OTDSQYDN SKI8_HUMAN Affects Response To Substance [24]
DNA-binding protein RFXANK (RFXANK) OTDX1026 RFXK_HUMAN Affects Response To Substance [24]
Transcription initiation factor TFIID subunit 1 (TAF1) OTDYS5G4 TAF1_HUMAN Affects Response To Substance [122]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7) OTE0EG10 EFCB7_HUMAN Affects Response To Substance [24]
Glucose-6-phosphate isomerase (GPI) OTEGSRXG G6PI_HUMAN Affects Response To Substance [24]
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR) OTEOT8GI GFRP_HUMAN Decreases Response To Substance [108]
Tyrosine-protein phosphatase non-receptor type 13 (PTPN13) OTESFZSO PTN13_HUMAN Increases Response To Substance [108]
Rho GDP-dissociation inhibitor 1 (ARHGDIA) OTEXWJDO GDIR1_HUMAN Affects Response To Substance [123]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Increases Response To Substance [44]
Serglycin (SRGN) OTFAVSX0 SRGN_HUMAN Affects Response To Substance [24]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A) OTFBU4GD P3C2A_HUMAN Affects Response To Substance [24]
Laminin subunit alpha-2 (LAMA2) OTFROQWE LAMA2_HUMAN Increases Response To Substance [27]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [24]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1) OTGPN3P8 TIA1_HUMAN Affects Response To Substance [24]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Affects Response To Substance [24]
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Affects Response To Substance [67]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Affects Response To Substance [24]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Response To Substance [26]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Response To Substance [124]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Increases Response To Substance [44]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Decreases Response To Substance [125]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Affects Response To Substance [24]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Affects Response To Substance [24]
Polycystin-2 (PKD2) OTIXBU8H PKD2_HUMAN Increases Response To Substance [108]
G/T mismatch-specific thymine DNA glycosylase (TDG) OTJB0YIH TDG_HUMAN Affects Response To Substance [24]
E3 ubiquitin-protein ligase FANCL (FANCL) OTJC7QPQ FANCL_HUMAN Affects Response To Substance [24]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1) OTJISZOX PLCE1_HUMAN Decreases Response To Substance [108]
Transmembrane protein 168 (TMEM168) OTJKZ6G9 TM168_HUMAN Affects Response To Substance [24]
Plakophilin-2 (PKP2) OTJOVF68 PKP2_HUMAN Decreases Response To Substance [108]
C-X-C chemokine receptor type 6 (CXCR6) OTK9R50G CXCR6_HUMAN Decreases Response To Substance [44]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Response To Substance [108]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1) OTKBUQXP NDUA1_HUMAN Affects Response To Substance [24]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Response To Substance [108]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases ADR [16]
Galectin-4 (LGALS4) OTKQCG0H LEG4_HUMAN Decreases Response To Substance [108]
Methylsterol monooxygenase 1 (MSMO1) OTKV62RZ MSMO1_HUMAN Affects Response To Substance [24]
Leukocyte surface antigen CD47 (CD47) OTLDZ0KZ CD47_HUMAN Decreases Response To Substance [44]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Affects Response To Substance [24]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Increases Response To Substance [109]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [26]
Peptidyl-prolyl cis-trans isomerase B (PPIB) OTLPH6KN PPIB_HUMAN Affects Response To Substance [24]
Annexin A8 (ANXA8) OTLSSQCY ANXA8_HUMAN Increases Response To Substance [108]
Keratin, type II cytoskeletal 7 (KRT7) OTLT3JFN K2C7_HUMAN Increases Response To Substance [108]
Lysosome-associated membrane glycoprotein 2 (LAMP2) OTLUGEJC LAMP2_HUMAN Affects Response To Substance [24]
Peroxiredoxin-2 (PRDX2) OTLWCY9T PRDX2_HUMAN Affects Response To Substance [24]
Hemicentin-1 (HMCN1) OTLZAS0P HMCN1_HUMAN Increases Response To Substance [27]
Furin (FURIN) OTM2665Z FURIN_HUMAN Decreases Response To Substance [44]
NADH dehydrogenase iron-sulfur protein 8, mitochondrial (NDUFS8) OTMEAWKO NDUS8_HUMAN Affects Response To Substance [24]
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8) OTMFG2YY ALG8_HUMAN Affects Response To Substance [24]
Glutathione S-transferase Mu 5 (GSTM5) OTMMBFY8 GSTM5_HUMAN Decreases Response To Substance [44]
Unconventional myosin-Va (MYO5A) OTMWLP3E MYO5A_HUMAN Increases Response To Substance [108]
Integral membrane protein 2B (ITM2B) OTMXEPXB ITM2B_HUMAN Affects Response To Substance [24]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2) OTMZD4PW SUCB1_HUMAN Affects Response To Substance [24]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Increases Response To Substance [108]
L-lactate dehydrogenase A chain (LDHA) OTN7K4XB LDHA_HUMAN Increases Response To Substance [126]
Proto-oncogene serine/threonine-protein kinase mos (MOS) OTNMQPFJ MOS_HUMAN Increases ADR [16]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases ADR [16]
Calcium-activated potassium channel subunit alpha-1 (KCNMA1) OTNYXOZO KCMA1_HUMAN Affects Response To Substance [24]
G-protein coupled receptor 35 (GPR35) OTO23NRK GPR35_HUMAN Decreases Response To Substance [108]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Increases Response To Substance [108]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Response To Substance [127]
Arginine/serine-rich protein 1 (RSRP1) OTOAZLCL RSRP1_HUMAN Affects Response To Substance [24]
Malectin (MLEC) OTOPGRF5 MLEC_HUMAN Affects Response To Substance [24]
Oncostatin-M-specific receptor subunit beta (OSMR) OTORWHPL OSMR_HUMAN Increases Response To Substance [108]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Response To Substance [128]
Delta(24)-sterol reductase (DHCR24) OTP301JW DHC24_HUMAN Affects Response To Substance [24]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Affects Response To Substance [24]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [24]
Prostaglandin E synthase 3 (PTGES3) OTPPQWI0 TEBP_HUMAN Affects Response To Substance [24]
Large ribosomal subunit protein uL23 (RPL23A) OTPYLCCX RL23A_HUMAN Decreases Response To Substance [44]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Response To Substance [44]
Eukaryotic translation initiation factor 5A-1 (EIF5A) OTQ8DJX5 IF5A1_HUMAN Increases Response To Substance [108]
Membrane cofactor protein (CD46) OTQ8NWJD MCP_HUMAN Increases Response To Substance [44]
Glutamine--fructose-6-phosphate aminotransferase 1 (GFPT1) OTQBDO45 GFPT1_HUMAN Decreases Response To Substance [108]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Decreases Response To Substance [129]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [24]
Keratin, type I cytoskeletal 23 (KRT23) OTQW6UAG K1C23_HUMAN Increases Response To Substance [27]
Fibroblast growth factor 5 (FGF5) OTQXGHBY FGF5_HUMAN Affects Response To Substance [24]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Affects Response To Substance [24]
Nuclear body protein SP140 (SP140) OTQZHFMT SP140_HUMAN Affects Response To Substance [24]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Response To Substance [27]
E3 ubiquitin-protein ligase CHFR (CHFR) OTRAD2TT CHFR_HUMAN Decreases Response To Substance [130]
Large ribosomal subunit protein mL63 (MRPL57) OTRB659E RT63_HUMAN Affects Response To Substance [24]
Protein CREG1 (CREG1) OTRHJ8HK CREG1_HUMAN Affects Response To Substance [24]
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) OTRHPFO2 AN32A_HUMAN Affects Response To Substance [24]
Retinol-binding protein 1 (RBP1) OTRP1MFC RET1_HUMAN Increases Response To Substance [108]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Response To Substance [108]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Increases Response To Substance [108]
Arrestin-C (ARR3) OTRZ00CH ARRC_HUMAN Decreases Response To Substance [44]
MHC class I polypeptide-related sequence B (MICB) OTS2DVDW MICB_HUMAN Increases Response To Substance [108]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [24]
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B) OTS9YK3E KCC2B_HUMAN Affects Response To Substance [24]
Lumican (LUM) OTSRC874 LUM_HUMAN Decreases Response To Substance [27]
Rhotekin (RTKN) OTSS8XR6 RTKN_HUMAN Decreases Response To Substance [131]
3-phosphoinositide-dependent protein kinase 1 (PDPK1) OTT09ZVP PDPK1_HUMAN Decreases Response To Substance [115]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Affects Response To Substance [24]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Decreases Response To Substance [27]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Affects Response To Substance [24]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Response To Substance [132]
Amyloid beta precursor like protein 2 (APLP2) OTTFE53M APLP2_HUMAN Affects Response To Substance [24]
Collagen alpha-1(XV) chain (COL15A1) OTTFKK18 COFA1_HUMAN Decreases Response To Substance [27]
Fascin (FSCN1) OTTGIHTM FSCN1_HUMAN Increases Response To Substance [108]
Keratin, type I cytoskeletal 13 (KRT13) OTTYSKGX K1C13_HUMAN Decreases Response To Substance [44]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Decreases Response To Substance [133]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Decreases Response To Substance [44]
N-acetylgalactosaminyltransferase 7 (GALNT7) OTUJSCAO GALT7_HUMAN Affects Response To Substance [24]
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (DAD1) OTUUNQBT DAD1_HUMAN Increases ADR [16]
Mitochondrial Rho GTPase 2 (RHOT2) OTV8WT2L MIRO2_HUMAN Affects Response To Substance [24]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Decreases Response To Substance [27]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [26]
Integrin beta-1-binding protein 1 (ITGB1BP1) OTVQFNGS ITBP1_HUMAN Affects Response To Substance [24]
U2 small nuclear ribonucleoprotein A' (SNRPA1) OTWJZFAP RU2A_HUMAN Affects Response To Substance [24]
Decorin (DCN) OTWLJL7K PGS2_HUMAN Decreases Response To Substance [27]
Glypican-3 (GPC3) OTWS8WSW GPC3_HUMAN Increases Response To Substance [27]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Response To Substance [134]
Transmembrane protein 59 (TMEM59) OTX4EKES TMM59_HUMAN Affects Response To Substance [24]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15) OTX8SZOT NUD15_HUMAN Affects Response To Substance [24]
Metallothionein-1E (MT1E) OTXJKU4Y MT1E_HUMAN Increases Response To Substance [44]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3) OTXL10N9 NDUA3_HUMAN Affects Response To Substance [24]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [116]
Neuroendocrine protein 7B2 (SCG5) OTXSJMT1 7B2_HUMAN Affects Response To Substance [24]
Peripheral myelin protein 22 (PMP22) OTXWYWCZ PMP22_HUMAN Decreases Response To Substance [44]
Collagen alpha-2(I) chain (COL1A2) OTY7G382 CO1A2_HUMAN Increases Response To Substance [27]
Bone morphogenetic protein 7 (BMP7) OTYATP2K BMP7_HUMAN Increases Response To Substance [44]
Serine/threonine-protein phosphatase PP1-beta catalytic subunit (PPP1CB) OTYFTYFR PP1B_HUMAN Affects Response To Substance [24]
Ferritin light chain (FTL) OTYQA8A6 FRIL_HUMAN Decreases Response To Substance [44]
Proteasome subunit beta type-1 (PSMB1) OTYRFBAH PSB1_HUMAN Affects Response To Substance [24]
Procathepsin L (CTSL) OTYTUW29 CATL1_HUMAN Increases Response To Substance [44]
ADP-ribosylation factor 3 (ARF3) OTYYQX85 ARF3_HUMAN Affects Response To Substance [24]
V-type proton ATPase catalytic subunit A (ATP6V1A) OTYZ2S9E VATA_HUMAN Affects Response To Substance [24]
Mitochondrial import inner membrane translocase subunit Tim13 (TIMM13) OTYZQJD3 TIM13_HUMAN Affects Response To Substance [24]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Decreases Response To Substance [135]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [24]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Affects Response To Substance [24]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [24]
------------------------------------------------------------------------------------
⏷ Show the Full List of 478 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast Cancer DC28REP N. A. Phase 1 [136]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01063517) Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7519).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Paclitaxel FDA Label
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 May 7;12(7):871-878.
7 Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65.
8 PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS One. 2014 Dec 22;9(12):e114583. doi: 10.1371/journal.pone.0114583. eCollection 2014.
9 Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. J Med Chem. 2017 Feb 23;60(4):1262-1271. doi: 10.1021/acs.jmedchem.6b00990. Epub 2016 Dec 21.
10 The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.
11 Iron overload inhibits cell proliferation and promotes autophagy via PARP1/SIRT1 signaling in endometriosis and adenomyosis. Toxicology. 2022 Jan 15;465:153050. doi: 10.1016/j.tox.2021.153050. Epub 2021 Nov 23.
12 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.
13 MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem. 2011 Apr 8;286(14):12157-65. doi: 10.1074/jbc.M110.198804. Epub 2011 Feb 1.
14 Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet. 2018 Aug;50(8):1086-1092. doi: 10.1038/s41588-018-0170-4. Epub 2018 Jul 16.
15 BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012 Jun 10;44(7):751-9. doi: 10.1038/ng.2323.
16 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
17 Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
18 Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
19 Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
20 Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. Anticancer Res. 2008 May-Jun;28(3A):1593-602.
21 Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
22 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
23 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 2006 Jan 8;231(1):49-64. doi: 10.1016/j.canlet.2005.01.018.
24 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
25 Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005 Jan 1;62(1):61-8. doi: 10.1002/pros.20117.
26 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
27 Microarray-based detection and expression analysis of extracellular matrix proteins in drug?resistant ovarian cancer cell lines. Oncol Rep. 2014 Nov;32(5):1981-90. doi: 10.3892/or.2014.3468. Epub 2014 Sep 9.
28 Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med. 2011 Jan 26;3(67):67ra7. doi: 10.1126/scitranslmed.3001922.
29 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
30 Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
31 Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
32 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
33 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
34 Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
35 Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
36 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
37 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
38 Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
39 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
40 FaDu cell characteristics induced by multidrug resistance. Oncol Rep. 2011 Nov;26(5):1189-95. doi: 10.3892/or.2011.1418. Epub 2011 Aug 10.
41 Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
42 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
43 Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004 Nov 15;64(22):8397-404. doi: 10.1158/0008-5472.CAN-04-1612.
44 cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.
45 [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
46 Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
47 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
48 Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
49 Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
50 CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
51 A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granulose-like tumor cell line (KGN). Endocrinology. 2004 Apr;145(4):1860-9.
52 The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 2005 May;19(5):1170-80.
53 Paclitaxel inhibits N-acetyltransferase activity and gene expression in human stomach tumor cells (SC-M1). Res Commun Mol Pathol Pharmacol. 2004;115-116:21-38.
54 Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol. 2009 Jun 16;53(24):2298-305.
55 Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32.
56 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
57 Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
58 Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
59 Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells. Chem Res Toxicol. 2019 Feb 18;32(2):255-264. doi: 10.1021/acs.chemrestox.8b00269. Epub 2019 Jan 22.
60 Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
61 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
62 Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005 Jul;4(7):716-9. doi: 10.4161/cbt.4.7.1782. Epub 2005 Jul 2.
63 Regulation of retinoschisin secretion in Weri-Rb1 cells by the F-actin and microtubule cytoskeleton. PLoS One. 2011;6(6):e20707. doi: 10.1371/journal.pone.0020707. Epub 2011 Jun 27.
64 Norcantharidin combined with paclitaxel induces endoplasmic reticulum stress mediated apoptotic effect in prostate cancer cells by targeting SIRT7 expression. Environ Toxicol. 2021 Nov;36(11):2206-2216. doi: 10.1002/tox.23334. Epub 2021 Jul 16.
65 CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chem Biol Interact. 2016 Dec 25;260:1-12. doi: 10.1016/j.cbi.2016.10.014. Epub 2016 Oct 18.
66 Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Chem Biol Interact. 2020 Jan 5;315:108865. doi: 10.1016/j.cbi.2019.108865. Epub 2019 Oct 16.
67 The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
68 The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. Gynecol Endocrinol. 2009 May;25(5):287-93. doi: 10.1080/09513590802530924.
69 Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int. 2003 Apr;42(5):419-29. doi: 10.1016/s0197-0186(02)00132-8.
70 Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
71 Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 7;25(3):94-102. doi: 10.1016/j.cyto.2003.10.004.
72 Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother. 2003 Mar;52(3):185-93. doi: 10.1007/s00262-002-0357-4. Epub 2003 Feb 7.
73 pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
74 Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res. 2005 Oct 1;65(19):8628-34. doi: 10.1158/0008-5472.CAN-05-1059.
75 Genotoxic, cytotoxic, and apoptotic effects of Hypogymnia physodes (L.) Nyl. on breast cancer cells. Environ Toxicol. 2014 May;29(7):804-13. doi: 10.1002/tox.21809. Epub 2012 Aug 21.
76 ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol. 2004 Jun;24(6):1499-504.
77 Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem. 1999 Mar 19;274(12):8208-16. doi: 10.1074/jbc.274.12.8208.
78 Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.
79 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
80 Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation. J Biochem Mol Toxicol. 2023 May;37(5):e23313. doi: 10.1002/jbt.23313. Epub 2023 Jan 22.
81 Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008 Feb 1;112(3):596-607. doi: 10.1002/cncr.23223.
82 Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x.
83 Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.
84 Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res. 2003 Jun;9(6):2366-73.
85 Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999 Jul;5(7):1876-83.
86 Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway. Breast Cancer Res Treat. 2011 Jul;128(1):57-68. doi: 10.1007/s10549-010-1076-8. Epub 2010 Jul 28.
87 Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008 Feb;13(2):259-71. doi: 10.1007/s10495-007-0165-6.
88 Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem. 2005 Jan;38(1):50-7. doi: 10.1016/j.clinbiochem.2004.09.012.
89 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
90 Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci. 2010 May;115(1):118-30. doi: 10.1093/toxsci/kfq028. Epub 2010 Jan 27.
91 Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). J Orthop Res. 2005 Sep;23(5):988-94. doi: 10.1016/j.orthres.2005.01.018. Epub 2005 Apr 25.
92 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol. 2001 Feb;59(2):254-62. doi: 10.1124/mol.59.2.254.
93 Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):55-62. doi: 10.1016/j.taap.2005.06.020. Epub 2005 Jul 26.
94 Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol. 2005 Jul 1;70(1):13-21. doi: 10.1016/j.bcp.2005.04.017.
95 Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.
96 PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol. 2009 Apr 15;77(8):1348-57. doi: 10.1016/j.bcp.2009.01.008. Epub 2009 Jan 24.
97 Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis. 1997;2(5):463-70. doi: 10.1023/a:1026422111457.
98 Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Anticancer Drugs. 2001 Nov;12(10):797-800. doi: 10.1097/00001813-200111000-00002.
99 Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
100 Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol. 2010 Sep 15;80(6):884-94. doi: 10.1016/j.bcp.2010.04.018. Epub 2010 Apr 22.
101 Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
102 Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
103 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. Int J Clin Oncol. 2001 Jun;6(3):128-31. doi: 10.1007/pl00012094.
104 Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther. 2006 Apr;5(4):380-5. doi: 10.4161/cbt.5.4.2477. Epub 2006 Apr 4.
105 MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene. 2004 Sep 29;340(1):53-9. doi: 10.1016/j.gene.2004.06.013.
106 Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
107 High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010 Jul 1;70(13):5486-96. doi: 10.1158/0008-5472.CAN-10-0713. Epub 2010 Jun 8.
108 Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
109 E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
110 Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.
111 [Correlation of sorcin overexpression to multidrug resistance of human gastric cancer cell line SGC7901]. Ai Zheng. 2008 Apr;27(4):337-42.
112 Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
113 CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
114 Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. doi: 10.1007/s11095-006-0136-6. Epub 2006 Jun 8.
115 Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
116 Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
117 Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology. 2016 Jul 15;365:48-58. doi: 10.1016/j.tox.2016.07.016. Epub 2016 Jul 27.
118 CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010 Dec;30(12):4791-8.
119 CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mllerian tumor). Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.
120 ATF3 inhibits arsenic-induced malignant transformation of human bronchial epithelial cells by attenuating inflammation. Toxicology. 2021 Aug;460:152890. doi: 10.1016/j.tox.2021.152890. Epub 2021 Aug 6.
121 Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006 Dec;5(12):3248-57. doi: 10.1158/1535-7163.MCT-06-0227.
122 MIAT shuttled by tumor-secreted exosomes promotes paclitaxel resistance in esophageal cancer cells by activating the TAF1/SREBF1 axis. J Biochem Mol Toxicol. 2023 Aug;37(8):e23380. doi: 10.1002/jbt.23380. Epub 2023 May 3.
123 Reduced expression of Rho guanine nucleotide dissociation inhibitor-alpha modulates the cytotoxic effect of busulfan in HEK293 cells. Anticancer Drugs. 2007 Mar;18(3):333-40. doi: 10.1097/CAD.0b013e328011fd7f.
124 Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol. 2011 Nov 15;82(10):1384-90. doi: 10.1016/j.bcp.2011.06.007. Epub 2011 Jun 13.
125 Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process. Environ Toxicol. 2021 Sep;36(9):1758-1764. doi: 10.1002/tox.23296. Epub 2021 May 28.
126 Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem. 2011 Mar 24;54(6):1599-612. doi: 10.1021/jm101007q. Epub 2011 Feb 18.
127 Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells. Chem Biol Interact. 2015 Jun 25;235:17-26. doi: 10.1016/j.cbi.2015.04.005. Epub 2015 Apr 10.
128 Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11636-41. doi: 10.1073/pnas.1934692100. Epub 2003 Sep 16.
129 Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005 Jun;124(6):1300-7. doi: 10.1111/j.0022-202X.2005.23720.x.
130 Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
131 Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 2004 Nov 18;23(54):8731-42. doi: 10.1038/sj.onc.1208106.
132 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
133 Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2011 Jun 1;9(6):681-9. doi: 10.6004/jnccn.2011.0056.
134 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
135 Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis. 2006 Dec;24(3):525-30. doi: 10.1016/j.nbd.2006.08.014. Epub 2006 Sep 28.
136 ClinicalTrials.gov (NCT00707707) Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer